This year’s conference drew about 10 thousand attendees to Lisbon, Portugal.
In the company’s Phase III study, 93 percent of subjects improved on an obstacle course designed to gauge light sensitivity.
CEO Brent Saunders says allowing patent challenges through the courts and patent office is an unfair burden.
Suit claims ‘anticompetitive scheme’ has hindered Xiidra’s entry into Medicare Part D plans.
Formulations include 'Klarity Drops,' a patented formulation developed by Richard Lindstrom, MD.
Sightbox will continue to provide lenses from all major manufacturers.
The agency’s target action date for deciding whether to approve the drug is Feb. 25.
Aerie said it initially plans to use the sustained-release technology with its wet AMD candidate.
The introduction of biosimilars and new therapeutic products over the next three years may disrupt the anti-VEGF segment.
The agency said many ophthalmologists use it during cataract surgery in an attempt to prevent endophthalmitis.
The retina specialist charged Medicare per eye patient, even though he repackaged single-use Lucentis vials into multiple syringes to treat several patients.
Panelists discuss IOP’s value in referring patients.
Tailored stent selection is critical, one speaker said.
Surgeons reported high levels of patient satisfaction and glasses independence in comparison studies.
The trial is designed to evaluate different preventive strategies in diabetic and non-diabetic patients.
There were no statistically significant differences using FLACS or phaco for all studied outcome measures, the speaker said.
Speaker says public systems will not pay more for FLACS than conventional phaco.
Speakers described their use of the KAMRA and Raindrop inlays.
Topics included patient outcomes versus LASIK and complications, such as suction loss.
Speakers questioned when and whether patients should be treated, as well as what technology to use.
Advanced microscopes and OCT devices were among the instruments showcased at the meeting.
Speakers provided updates on tissue-engineered corneas, limbal cell transplantation, and regeneration of the crystalline lens.
Novartis will pay ThromboGenics €53.7 million in cash and make an equity investment of €10 million.
The conference is the largest ophthalmic event in the world and drew 25,430 attendees in 2016.
You are not currently logged in.
©2017 Market Scope
Lost your Password